Prostate Cancer Studies Currently Recruiting Participants at the University of Chicago Comprehensive Cancer Center

Study Number Title
IRB13-0756 Quantitative DCEMRI of Prostate Cancer ¿ Correlation with Gold Standards
IRB14-0081 Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients with Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma
IRB14-0105 A Phase 1, Open-Label, Dose Escalation Study of MGA271 (Fc-optimized Humanized Anti-B7-H3 Monoclonal Antibody) in Patients with Refractory B7-H3-Expressing Neoplasms or Neoplasms Whose Vasculature Expresses B7-H3
12803B Quality of Life after Radical Prostatectomy
12278A Clinical Urology Research Screening Protocol
15244B IRB 15244B: CALGB 90203: Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer
14934A Radiotherapy for Prostate Cancer: Dosimetric and Clinical Outcomes in the IMRT Era
10-174-B Feasibility of Collection & Analysis of Circulating and Disseminated Tumor Cells from men with Advanced Prostate Cancer
10-487-A The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
10-625-A A feasibility study of oral hormonal therapy and radiation for non-metastatic, intermediate or high risk prostate cancer in men 70 and older or with medical comorbidities
11-0110 CALGB 70807: The Men¿s Eating and Living (MEAL) Study: A Randomized Trial of Diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance
11-0061 Evaluation of endorectal MRI for risk stratification, treatment planning, and workup after biochemical failure in patients with adenocarcinoma of the prostate
11-0621 A Phase I/II Study of Docetaxel, Prednisone and Pazopanib in Men with Metastatic Castrate-resistant cancer and poor-risk features.
12-0114 The CATCH Prostate Cancer Trial: Cabazitaxel and Tasquinimod in Men With Castration-Resistant Heavily Pre-treated Prostate Cancer

To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.